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Summary 
Background 
Malnourished and young children are particularly vulnerable to severe forms of tuberculosis and 
poor treatment response. Current World Health Organization (WHO) dosing guidelines are only 
based on weight, which may lead to systematic underdosing and worse outcomes in these 
vulnerable children. We evaluate and quantify the population impact of current WHO guidelines 
for drug-susceptible tuberculosis in children in the 20 countries with highest disease burden.  
Methods  
Using an integrated model which links country-specific individual-level demographic data to 
pharmacokinetic, outcome, and epidemiological models, we assessed tuberculosis treatment 
outcomes in children under five years of age following the current WHO guidelines and two 
alternative dosing strategies: a simple algorithm that utilizes age, weight, and available 
formulations, and an individualized algorithm without dose limitations. 
Findings 
We estimated that 57,234/133,302 (43%) treated under-5 tuberculosis cases would be 
underdosed with WHO dosing and only 47% of children would reach the rifampicin exposure 
target. Underdosing and subtherapeutic exposures were more common among malnourished 
children. The simple proposed dosing approach improved estimated rifampicin target exposure 
attainment to 62% and equalized outcomes by nutritional status. An estimated one-third of 
unfavorable treatment outcomes might be resolved with this dosing strategy, saving a minimum 
of 2423 children in these countries annually. With individualized dosing approaches, almost all 
children could achieve adequate exposure for cure. !
Interpretation 
  1 
This work demonstrates that a simple change in dosing procedure to include age and nutritional 
status, requiring no additional measurements or new drug formulations, is one approach to 
improve tuberculosis treatment outcomes in children, especially malnourished children who are 
at high risk of mortality.  
Funding 
NICHD, UK Medical Research Council. 
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Research in Context 
Evidence before this study 
We searched PubMed for studies published before Dec 1, 2018 with the search terms "child*" 
AND "tuberc*" AND ("outcome” OR “exposure” OR “pharmaco*”) AND (“dose*” OR 
“dosing” OR “treatment”) in the title or abstract. Our search identified 652 studies, most of 
which pertained to diagnosis, latent tuberculosis or prevention, and drug-resistant forms were not 
considered. We also reviewed our personal files for additional relevant articles. Since the release 
of the first WHO child tuberculosis guidelines in 2006, 30 studies have reported tuberculosis 
treatment outcomes in children. In 20 of these studies, unfavorable outcomes, including 
treatment failure or death, were greater than 10%. Young age (< 5 years), malnutrition, HIV 
infection, and extra-pulmonary tuberculosis (e.g., meningitis) have all been associated with 
worse outcomes. Underdosing or subtherapeutic drug levels have been reported in >50% of child 
subjects in 17 studies, 8 of which utilized the current WHO dosing guidelines. No clinical studies 
in children with tuberculosis have been conducted with alternative dosing approaches to the 
standard weight-based method (i.e., mg/kg); however, several studies conclude that improved 
dosing is required to adequately treat children. 
Added value of this study 
To our knowledge, this is the first study to use an integrative modeling approach which links 
pharmacological with epidemiological models to evaluate the population-level impact of 
tuberculosis dosing in children. We utilized individual child demographic data (n>300,000) from 
20 countries with high tuberculosis incidence to predict individual drug exposure profiles and 
link them to treatment response and epidemiological outcomes. Our innovative approach enables 
true representation of populations vulnerable to treatment failure in realistic proportions, 
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including very young children and children who are malnourished. Furthermore, we compare 
drug exposure and treatment outcomes following the current WHO dosing guidelines, which are 
based solely on a child’s weight, with a newly proposed dosing approach that incorporates age 
and nutritional status. Our study is the first to show that a weight-based approach is inadequate 
for tuberculosis treatment where many ill children are malnourished. To that end, a simple 
change in dosing approach can drastically improve tuberculosis treatment outcomes in the most 
vulnerable children. 
Implications of all the available evidence  
The current WHO dosing recommendations for children with drug-sensitive tuberculosis are not 
sufficient to cure disease in all children, especially in malnourished and young children who are 
particularly vulnerable to severe forms, poor treatment outcomes, and death. The dosing method 
proposed in this study is simple, directly implementable, would not require any additional 
measurements by tuberculosis care providers, utilizes currently available fixed-dose combination 
formulations, and would save many children’s lives. Importantly, this work can advise future 
dosing recommendations for young children with tuberculosis. 
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Background 
Childhood tuberculosis is among the top 10 killers of children under five years of age.1 Although 
global reports on leading causes of child mortality historically had omitted tuberculosis, recent 
estimates suggest that 191,000 children younger than five years died of tuberculosis in 2015.1 
Late or missed diagnosis of tuberculosis is a primary driver of mortality among children, but 
evidence from clinical studies also show that even when diagnosed and treated, tuberculosis 
outcomes are still far from ideal in countries with high incidence.2,3 Narrowing the treatment-
response gap for children with tuberculosis will be a pivotal step toward curbing childhood 
mortality and will help move us towards the goal of Zero Deaths from childhood tuberculosis.4  
 
Tuberculosis disease severity, compromised immune response, and suboptimal treatment all 
contribute to morbidity and mortality from childhood tuberculosis. Young children are 
vulnerable to severe forms of tuberculosis including disseminated disease (e.g., tuberculosis 
meningitis and miliary tuberculosis), which is more difficult to cure.5 Likewise, comorbidities 
that impair immune function (e.g., HIV infection, malnutrition) have been linked with lower 
survival.6,7 Early and accurate disease detection as well as initiation of appropriate supportive 
therapy (e.g., anti-retroviral therapy in HIV co-infection and nutritional support in 
undernourished) are important for proper tuberculosis disease management. Further, adequate 
drug exposure of anti-tuberculosis treatment is essential for optimal disease outcomes and 
preventing the development of drug-resistant tuberculosis, which has substantially worse 
outcomes.8,9 While many factors certainly contribute to tuberculosis disease outcome, the precise 
impact of each factor has not been quantified. Optimizing treatment dosing for children is one 
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known and established intervention that can be easily controlled and is an attractive, simple, and 
efficient strategy for tuberculosis policy change that could immediately benefit children’s lives. 
 
Pediatric dosing guidelines, including the WHO guidelines for child tuberculosis,10 are 
historically derived based on weight and may leave young and malnourished children vulnerable 
to underdosing. Flat weight-based dosing (e.g., mg/kg for all ages) assumes a linear relationship 
between dose requirement and weight, neglecting basic principles of developmental 
pharmacology.11 In general, weight is a good indicator of a child’s capacity to distribute, 
metabolize, and eliminate drug if the child is well-nourished and school-aged or older. However, 
young children undergo dynamic changes in metabolic capacity and body composition during 
growth that alter drug pharmacokinetics.11 These changes are often correlated to weight using ¾ 
power laws, which forms the basis for weight-based dosing where higher mg/kg doses are 
required in very young children. Further, weight and metabolic rate do not correlate well in 
malnourished children who have the same metabolic potential as healthy children of equal age. 
The current tuberculosis dosing guidelines do not consider allometry, age, or malnutrition, which 
is likely to result with systematic underexposure of young and malnourished children. For 
example, in the case of children one year of age, a child with a normal weight of 9 kg receives 
twice as much drug as a malnourished child who weighs 6 kg with WHO weight band dosing,12 
but both children would be expected to eliminate the drug at similar rates. Correcting 
systematically low drug exposures in the most vulnerable children by modifying drug dosing is 
an unrecognized and simple area of intervention that could greatly improve outcomes in all of 
pediatric medicine.  
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We conducted a modeling study to estimate the prevalence of potential underdosing of first-line 
anti-tuberculosis drugs and the consequent impact on drug exposures and population outcomes 
(including mortality) in the 20 countries with the highest burden of childhood tuberculosis.  We 
used a novel, integrative modeling design which used real, individual-level child demographic 
data along with relevant population pharmacokinetic, exposure-response, and epidemiological 
models to minimize assumptions and to establish an environment representative of true 
conditions. To our knowledge, this is the first time a model such as this has been used. With this 
design, we estimated the impact of a revised dosing method which incorporates age and 
nutritional status, simply measured, on treatment outcomes compared to the current standard.  
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Methods 
The integrated model was created by linking individual child demographic data obtained from 
country-specific population health surveys with pharmacokinetic, pharmacodynamic (outcome), 
and epidemiological models (S1 Figure).  
 
Demographic Database 
We created a database of nationally-representative child populations under five years of age from 
publicly accessible survey data for the 20 countries with the highest total tuberculosis incidence 
(Table 1). These countries account for 82% of total estimated under-5 tuberculosis incidence.13 
The Demographic and Health Surveys (DHS) Program, a standardized international survey that 
collects accurate and representative data on health and nutrition for more than 90 countries with 
large sample sizes, was used as the primary data source.14 For eight of the 20 countries, child 
DHS data were unavailable, and other government administered survey sources were used. 
Child-specific anthropometrics, gender, age, and nutritional status markers (height-for-age z-
score [HAZ], weight-for-age z-score [WAZ], weight-for-height z-score [WHZ], and body mass 
index-for-age z-score [BAZ]) were extracted from each database. When unavailable from the 
database, nutritional markers were calculated in R 3.4.2 (R Core Team; Vienna, Austria) using 
the WHO’s Anthro software.15 Children with expected or actual weight less than 4 kg or 
physiologically implausible nutritional z-scores were excluded.12,15  
 
Dosing Methods  
All children were sampled from the above-mentioned database as a potential child with drug-
sensitive tuberculosis disease. The WHO-recommended fixed-dose combination (FDC) 
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formulation for intensive phase treatment (75 mg rifampicin, 50 mg isoniazid, 150 mg 
pyrazinamide) was used.12 Tuberculosis treatment was simulated for each child with two 
different dosing methods: the current standard, and a proposed simple algorithm to account for 
the effects of malnutrition. A third, individualized dosing method for each child was also 
explored. 
 
For the current standard dosing procedure, the most recent WHO childhood tuberculosis 
guidelines were used.10 In this method, children are dosed by weight bands (4-7 kg, 8-11 kg, 12-
15 kg, 16-24 kg, 25+) corresponding to incremental FDC tablet quantity and flat mg/kg dose 
range (S2 Table).12  
 
For the new proposed dosing procedure, we chose a simple method where underweight children 
would receive equal drug doses as normal weight children of the same age (Figure 1). This 
method was derived by evaluating what dose a child would receive if they were of normal 
weight. In this proposed method, children with good nutritional status (WAZ > 0) received 
weight-based dosing according to the WHO weight band algorithm.12 Children with poor 
nutritional status (WAZ < 0) received age-based (i.e., expected weight-based) dosing, receiving 
higher doses than would be received with the current method. This method utilizes the WHO-
recommended FDC formulation for children, is simple to implement in resource-limited clinical 
settings and minimizes the need for additional measurements. Furthermore, to facilitate using 
WAZ for dose determination, a simplified dosing chart resembling a child growth chart was 
constructed to eliminate any calculation requirements (see S3-S4 Figures for full page charts).  
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An individualized dosing scheme was also tested which utilized a developmental pharmacology-
driven approach to define the optimal dose. Here, rifampicin, isoniazid, and pyrazinamide doses 
were determined separately using drug-specific target exposures and individual pharmacokinetic 
parameter estimates, without constraint to available formulations or rounding (appendix, page 9). 
This method focused on ensuring that each child reached the target exposure for each drug. With 
these individualized doses, we explored optimized fixed-dose formulations and dose ratios that 
may be required for implementing this method.  
 
Exposure Simulations  
Drug exposures were estimated for rifampicin, isoniazid, and pyrazinamide using two published 
and peer-reviewed population pharmacokinetic models (appendix, page 9).16,17 Individual child 
pharmacokinetic parameters were sampled from the established population distribution, defined 
with median values and between-child variability. Pharmacokinetic profiles were simulated in R 
using Monte Carlo for each drug and dosing method assuming once-daily oral administration 
with full adherence to represent the most promising scenario (i.e., treatment completion). For 
isoniazid, pharmacokinetic profiles for both slow and fast acetylators were simulated.  
Pharmacokinetic data were summarized as area under the curve at steady state (AUCss) by 
integration of the pharmacokinetic profile over a desired period (day, week, month). 
 
Definition of Target Exposure and Outcome Predictions 
The simulated pharmacokinetic profiles were linked to drug exposure targets to predict 
tuberculosis treatment outcome. Target exposures for children are typically based on adult 
reference concentrations, so the AUCss targets of 23·4 mg*h/L for isoniazid and 427 mg*h/L for 
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pyrazinamide over 24 hours were used.17 For rifampicin, a child-specific target defined from an 
exposure-response model was used, where the relationship between rifampicin AUCss over one 
week (AUCwk) is related to the probability of unfavorable event (Punf), defined as death or 
treatment failure, aligning with the fact that rifampicin is the most important drug in the 
regimen.16 Using this model, we defined the rifampicin exposure target as AUCwk > 222 mg*h/L, 
which results in a Punf < 5%, and predicted the Punf for each child. 
 
Linkage to Epidemiological Models 
An epidemiological model was linked to the pharmacodynamic model to estimate the number of 
children who would experience an unfavorable outcome in the 20 countries included (appendix, 
page 13).18 The country- and age-specific median Punf was applied to age-disaggregated WHO 
tuberculosis notification data to estimate the number of unfavorable events.13 Notified cases were 
assumed to represent treated cases.  
 
Analysis 
All data manipulation, nutritional marker calculations, summary statistics, model simulations, 
and visualizations were performed in R. Children were considered underweight if WAZ < -2, 
stunted if HAZ < -2, and wasted if WHZ < -2. Malnutrition severity was defined based on z-
score: normal (z > 0), mildly malnourished (-2 < z < 0), moderately malnourished (-3 < z < -2), 
or severely malnourished (z < -3). Children were considered underdosed by current guidelines if 
the WHO-recommended dose was lower than the dose that child would have received with the 
proposed guidelines (i.e., if the weight-based dosing resulted in lower dose than the expected 
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weight-based dosing for an underweight child). Underexposure was defined as AUCss below the 
defined exposure target.  
 
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication.
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Results 
Population Characteristics 
Our database included individual-level anthropometric data from 388,209 children under five 
years of age from 20 high-burden tuberculosis countries. Overall, 27% of children were 
underweight, 36% were stunted, and 15% were wasted. Stunting was prevalent in most countries 
(>30% in 13 countries; Table 1). Bangladesh, India, and Ethiopia had high proportions of 
underweight children (>30%) and wasting was critically (>15%) or seriously (10-15%) high in 
five countries.  
 
Underdosing Prevalence 
We estimated that 43% of children or 57,234 of 133,302 treated under-5 tuberculosis cases 
would be underdosed following current guidelines, based on predicted underdosing by country 
(Figure 2). Among underweight children only, the prevalence of underdosing was consistently 
high (>70%) across all countries. Following the current dosing method, the average dose was 
16·0 mg/kg for rifampicin, 10·7 mg/kg for isoniazid, and 32·0 mg/kg for pyrazinamide. With the 
proposed dosing, average doses were 19·6 mg/kg for rifampicin, 13·1 mg/kg for isoniazid, and 
39·2 mg/kg for pyrazinamide. This dosing gap was consistent across age groups.  
 
Malnutrition Effects on Rifampicin Exposure Target Outcomes 
With current dosing guidelines, only 47% of all children were predicted to reach the defined 
rifampicin target exposure (Figure 3). Most cases of target attainment (>75%) occurred in 
children of adequate weight (WAZ >-2). Rifampicin target exposure attainment following 
current dosing guidelines was lower among malnourished children and lessened with increasing 
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malnutrition severity. The proposed dosing method improved outcomes not only for all children 
but also for those with poor nutritional status and equalized target outcomes across different 
measures of malnutrition and severity. This trend of improved exposure target outcomes with the 
proposed method was consistent in all 20 high burden countries (Figure 4). Target exposure 
trends for isoniazid and pyrazinamide are shown in S8 Figure and S9 Figure, respectively. 
 
Population Estimate of Unfavorable Outcome  
The median Punf for the study population following the current dosing regimen was 3·3%. 
Notably, very young (median Punf = 7·7%) or underweight (median Punf = 4·0%) children were 
predicted to be particularly vulnerable to poor treatment outcomes with current guidelines. The 
proposed dosing method improved treatment outcomes for all children (median Punf = 1·8%), 
with the best improvement seen in the very young (median Punf = 4·7%) and underweight 
(median Punf =1%).  Estimated Punf was more equal with the proposed and individualized dosing 
across varying WAZ (S10 Figure).  
 
Linking the exposure-response model to tuberculosis case notification data, we found that the 
number of treatment failures or deaths in children under five years decreased for all 20 high-
burden countries with the proposed dosing method (Table 2). Considering only treatment of 
notified cases, which represents 30% of the total estimated under-5 incidence in these 
countries,13 the proposed method would prevent treatment failure or death from tuberculosis in at 
least one-third of children predicted to have unfavorable outcome with current dosing practices 
(equivalent to 2423 actual cases saved per year, at minimum). This impact could be as high as 
7844 children saved if all estimated cases are considered (S9 Table).  
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Discussion 
In this study, we introduce a novel, integrative modeling approach which links pharmacologic 
with epidemiologic models to predict population-level outcomes for childhood tuberculosis. This 
is the first time that individual child demographic data, representative of true global populations, 
are used in this context. We included individual-level data from more than 300,000 children 
under five years of age from 20 high-burden tuberculosis countries, enabling true representation 
of malnourished children and populations at the highest risk of tuberculosis and severe disease. 
We compare the current WHO-recommended dosing guidelines with alternative dosing methods 
to show that simple modifications to dosing practices can improve anti-tuberculosis drug 
exposure and consequently, population outcomes for children with tuberculosis.  
  
Effective anti-tuberculosis therapy has drastically decreased child mortality from tuberculosis 
disease in recent decades.19 However, treatment failures and mortality rates are still high in many 
endemic areas, especially among children who are very young, malnourished, HIV infected, or 
have severe disease.2,3,20 Adequate treatment exposure is essential in these children for successful 
disease outcomes.  Our model predicted that less than half of children under five years of age 
would reach the rifampicin exposure target, a key drug for tuberculosis cure, with the current 
guidelines. Malnourished children had lower drug exposures and higher probabilities of 
unfavorable outcome. These findings support trends shown in clinical studies and reflect the 
inadequacy of current weight-based dosing recommendations that do not consider age or 
nutritional status. 
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With high malnutrition prevalence in tuberculosis-endemic countries, it is important to consider 
the treatment needs of malnourished children separately. Currently, the way malnourished 
children are distinguished from their well-nourished peers of the same age is by receiving less 
drug for the same disease, as evidenced by the percentage of potentially underdosed children in 
our model. In addition to receiving less drug, pathophysiological changes in the poor nutritional 
state such as malabsorption, increased renal clearance, and altered protein-binding capacity can 
further lead to variable and subtherapeutic drug exposures in malnourished children.21,22 All of 
these well-established factors suggest that malnourished children require higher anti-tuberculosis 
dosages to have an equal chance of cure.   
 
The simple dosing method proposed here shows that accounting for malnutrition could improve 
tuberculosis treatment outcomes in underweight children by delivering adequate drug exposure. 
With the proposed dosing method, more children reached target exposures compared to the 
current guidelines in all 20 countries evaluated, even those with low malnutrition prevalence. 
This method is a simple change from current guidelines that can be readily implemented in 
clinical practice. It would be easy-to-use by tuberculosis clinicians, even in remote settings, as it 
requires only the measurement of weight, age, gender, and estimation of nutritional status (i.e., 
WAZ for which a simple dosing chart could be used).  
 
When considering dose increases, the risk of toxicity must also be assessed. These drugs have 
high therapeutic margins and are well-tolerated in children even at higher doses, as routinely 
prescribed in tuberculosis meningitis.3,23,24 Additionally, no studies have reported decreased 
clearance of these drugs with malnutrition. Therefore, any concerns regarding administering 
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higher doses to underweight children are likely unjustified. Without established upper limits of 
exposure associated with toxicity, the benefit of higher dosages will likely outweigh any 
potential risk. Regardless, the risk/benefit ratio should be considered for malnourished children 
who are extremely vulnerable to death. 
 
Even with the proposed dosing method, treatment success was still far below desired targets 
(~90%). Further, drug exposure outcomes in normal weight children were suboptimal with both 
dosing methods. The proposed method is based on the minimum change required to make a 
sizeable impact. We constrained dosing to WHO-recommended dose ranges and FDC 
formulations, which may not be appropriate for all individuals. Precision dosing algorithms, 
which account for additional patient and/or disease factors that impact exposure (e.g., HIV 
infection, SLCO1B1 genotype, and NAT2 acetylator status), will likely be needed to achieve 
WHO targets with current therapeutics.20,22,25-27 Optimized FDC formulations were explored 
based on the individualized doses, but drug doses and dose ratios varied by pharmacokinetic 
model and isoniazid metabolizing capacity. Our work along with others16,28 suggests that higher 
anti-tuberculosis doses and new FDC formulations are needed to ensure optimal outcomes. 
However, it remains unclear from current pediatric pharmacologic data whether a single global 
FDC formulation can meet the needs of all children. One simple intermediate solution would be 
to develop a stand-alone, child-friendly rifampicin formulation to supplement current FDC 
tablets when higher dosages are necessary. 
 
Drug exposures were simulated using two pharmacokinetic models from distinct populations 
(India and South Africa) and applied in regionally and demographically similar populations. 
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Outcomes were predicted for all children with a pharmacodynamic model representative of an 
Indian population alone. These assumptions were made due to the lack of country-specific 
pharmacologic models and are a limitation of the study. Still, these models represent the only 
pediatric pharmacokinetic and pharmacodynamic models in the countries of interest and are of 
the highest quality. The two pharmacokinetic models differed slightly. Genetic diversity or other 
differences in patient demographics may explain the slight inequality we observed. However, 
whether the pharmacology truly does differ by region remains unclear as these questions were 
either not considered in the original trial design or lacked sufficient power to detect differences. 
It is imperative that future multi-regional studies are conducted and data sharing between 
countries is improved in order to fully understand dose-concentration-response relationships in 
children across the globe. 
 
Our study focused on evaluating tuberculosis treatment and obtaining adequate exposure for 
cure. The effects of non-pharmacological interventions for malnutrition, HIV co-infection, and 
extrapulmonary disease, independent of drug exposure, were not included in our model. These 
children at high risk of poor outcomes may require even higher doses and/or additional 
interventions to overcome a poor immune response or severe disease in order to have an equal 
chance of cure. Future pediatric studies should be designed to include these high-risk cohorts in 
order to establish drug efficacy targets for vulnerable populations and efficacy of additional 
pharmacological and non-pharmacological interventions if we hope to cure tuberculosis in all. 
 
Our epidemiological model accounted for age-related differences in disease risk, but malnutrition 
and HIV infection, both known to impact disease progression, were not included.  Malnutrition 
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impacts the immune system, increasing a child’s risk of progression to active tuberculosis, and 
the disease further exacerbates the child’s nutritional state.29 While the relationship between 
tuberculosis and malnutrition is well-known, the relative risk of disease progression in 
malnourished children has not been quantified. We assumed that the malnutrition prevalence 
among tuberculosis cases in our model matched the prevalence in our demographic database. In 
tuberculosis disease, we would expect more malnourished children than the general population, 
implying that our population-level estimates with the proposed dosing algorithm are 
conservative. Further, HIV status information was sparse in the demographic datasets, limiting 
our analysis to an HIV uninfected population. While we cannot make unique dose 
recommendations or predict outcomes for HIV co-infected children from this study, we would 
expect that the proposed dosing would improve exposure outcomes in HIV co-infected children, 
as these children are often malnourished. 
 
Less than half of the estimated one million child tuberculosis cases per year are represented in 
WHO notification data.13 Case detection is extremely low in children under five years of age due 
to diagnostic challenges and under-reporting.18 Clearly, finding and diagnosing children with 
tuberculosis is the highest priority for decreasing disease burden. However, this work shows that 
even with access to the correct treatment, an impact can be made by optimizing dosing. The 
minimum impact of implementing the proposed dosing strategy is 2423 fewer treatment failures 
or deaths annually in children under five years in these 20 high-burden countries, based on 
notified cases. Unfavorable outcomes could be reduced from 23,510 to 15,666 per year if we 
assume all estimated under-5 tuberculosis cases in these countries are diagnosed and treated. It is 
clear that while the proposed dosing method improves outcomes, treatment failures and deaths 
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still occur. Future studies that evaluate the impact of all key factors such as treatment, 
malnutrition, HIV status, etc. are imperative. Only by carefully studying and understanding the 
quantitative impact of all factors and unbiased efficacy predictions of targeted interventions can 
we move closer to achieving zero childhood deaths from tuberculosis. Acting on discoveries that 
could lead to simple adjustments in how we treat the most vulnerable of children is an important 
first step.  
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Tables 
Table 1. Study Population.   
   Nutritional Status, n (%)  
Survey, 
Year(s) Country  N Underweight Stunted Wasted 
Angola  6135 1139 (19) 2309 (38) 305 (5) DHS, 
< 1 year  1310 202 (15) 275 (21) 93 (7) 2015 
1-3 years  2528 518 (20) 1149 (45) 136 (5)  
3-5 years  2297 419 (18) 885 (39) 76 (3)  
       
Bangladesh  6857 2225 (32) 2522 (37) 972 (14) DHS, 
< 1 year  1236 216 (17) 203 (16) 202 (16) 2011 
1-3 years  2862 974 (34) 1162 (41) 405 (14)  
3-5 years  2759 1035 (38) 1157 (42) 365 (13)  
       
Brazil  4288 81 (2) 311 (7) 62 (1) PNDS, 
< 1 year  801 15 (2) 35 (4) 24 (3) 2006 
1-3 years  1721 29 (2) 149 (9) 21 (1)  
3-5 years  1766 37 (2) 127 (7) 17 (1)  
       
China  1729 74 (4) 220 (13) 76 (4) CHNS, 
< 1 year  233 7 (3) 35 (15) 13 (6) 2006 
1-3 years  708 28 (4) 95 (13) 32 (5)  
3-5 years  788 39 (5) 90 (11) 31 (4)  
       
DRC  7913 1835 (23) 3515 (44) 613 (8) DHS, 
< 1 year  1608 213 (13) 303 (19) 181 (11) 2013 
1-3 years  3275 725 (22) 1513 (46) 268 (8)  
3-5 years  3030 897 (30) 1699 (56) 164 (5)  
       
Ethiopia  9482 2850 (30) 4043 (43) 1095 (12) DHS, 
< 1 year  1839 289 (16) 243 (13) 307 (17) 2011 
1-3 years  3654 1253 (34) 1816 (50) 461 (13)  
3-5 years  3989 1308 (33) 1984 (50) 327 (8)  
       
India  221,113 75,869 (34) 85,069 (38) 44,323 (20) DHS, 
< 1 year  37,970 9541 (25) 8018 (21) 9968 (26) 2015 
1-3 years  90,396 31,759 (35) 38,196 (42) 18,274 (20)  
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3-5 years  92,747 34,569 (37) 38,855 (42) 16,081 (17)  
       
Indonesia  4398 850 (19) 1582 (36) 411 (9) IFLS, 
< 1 year  767 100 (13) 206 (27) 92 (12) 2006, 
1-3 years  1805 366 (20) 729 (40) 182 (10) 2007 
3-5 years  1826 384 (21) 647 (35) 137 (8)  
       
Kenya  18,424 2427 (13) 4995 (27) 989 (5) DHS, 
< 1 year  3478 233 (7) 437 (13) 192 (6) 2014 
1-3 years  7639 1102 (14) 2522 (33) 407 (5)  
3-5 years  7307 1092 (15) 2036 (28) 390 (5)  
       
Mozambique  9142 1178 (13) 3604 (39) 450 (5) DHS, 
< 1 year  1873 228 (12) 463 (25) 133 (7) 2011 
1-3 years  3893 545 (14) 1770 (45) 237 (6)  
3-5 years  3376 405 (12) 1371 (41) 80 (2)  
       
Myanmar  4138 763 (18) 1268 (31) 263 (6) DHS, 
< 1 year  786 67 (9) 73 (9) 60 (8) 2015 
1-3 years  1661 319 (19) 574 (35) 114 (7)  
3-5 years  1691 377 (22) 621 (37) 89 (5)  
       
Nigeria  24,076 6444 (27) 8720 (36) 3936 (16) DHS, 
< 1 year  4893 1027 (21) 921 (19) 1171 (24) 2013 
1-3 years  9631 2880 (30) 3930 (41) 1698 (18)  
3-5 years  9552 2537 (27) 3869 (41) 1067 (11)  
       
Pakistan  3011 787 (26) 1350 (45) 304 (10) DHS, 
< 1 year  520 110 (21) 115 (22) 73 (14) 2012 
1-3 years  1203 344 (29) 603 (50) 139 (12)  
3-5 years  1288 333 (26) 632 (49) 92 (7)  
       
Philippines  15,922 3510 (22) 5506 (35) 1043 (7) FNRI-NNS, 
< 1 year  2593 322 (12) 343 (13) 246 (9) 2015 
1-3 years  6089 1379 (23) 2322 (38) 451 (7)  
3-5 years  7240 1809 (25) 2841 (39) 346 (5)  
       
Russia  9665 282 (3) 919 (10) 828 (9) RLMS-HSE, 
< 1 year  1803 87 (5) 208 (12) 142 (8) 2006- 
1-3 years  4020 76 (2) 395 (10) 272 (7) 2015 
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3-5 years  3842 119 (3) 316 (8) 414 (11)  
       
South Africa  9691 671 (7) 2573 (27) 406 (4) NIDS, 
< 1 year  859 65 (8) 171 (20) 80 (9) 2008- 
1-3 years  4012 265 (7) 1310 (33) 158 (4) 2014 
3-5 years  4820 341 (7) 1092 (23) 168 (3)  
       
Tanzania  8735 1177 (13) 2961 (34) 400 (5) DHS, 
< 1 year  1773 169 (10) 310 (17) 128 (7) 2015 
1-3 years  3808 569 (15) 1525 (40) 170 (4)  
3-5 years  3154 439 (14) 1126 (36) 102 (3)  
       
Thailand  8688 593 (7) 1187 (14) 516 (6) MICS, 
< 1 year  987 67 (7) 140 (14) 84 (9) 2012  
1-3 years  3722 223 (6) 559 (15) 177 (5)  
3-5 years  3979 303 (8) 488 (12) 255 (6)  
       
Vietnam  3515 379 (11) 758 (22) 135 (4) MICS, 
< 1 year  592 26 (4) 44 (7) 32 (5) 2010  
1-3 years  1500 157 (10) 353 (24) 48 (3)  
3-5 years  1423 196 (14) 361 (25) 55 (4)  
       
Zambia  11,287 1687 (15) 4493 (40) 693 (6) DHS, 
< 1 year  2103 220 (10) 480 (23) 175 (8) 2014 
1-3 years  4669 782 (17) 2269 (49) 284 (6)  
3-5 years  4515 685 (15) 1744 (39) 234 (5)  
 
 
Underweight = weight-for-age z-score (WAZ)< -2; Stunted = height-for-age z-score (HAZ)< -2; 
Wasted = weight-for-height z-score (WHZ)< -2. CHNS = Chinese Health and Nutrition Surveys; 
DHS = Demographic and Health Surveys Program; DRC = Democratic Republic of the Congo; 
FNRI-NNS = Food and Nutrition Research Institute-National Nutrition Survey; IFLS = 
Indonesia Family Life Survey; MICS = Multiple Indicator Cluster Surveys; NIDS = National 
Income Dynamics Study; PNDS = Pesquisa Nacional de Demografia e Saude; RLMS = Russia 
Longitudinal Monitoring Survey- Higher School of Economics.  
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Table 2. Estimated number of treatment failures or deaths from tuberculosis per year in 
children under five years of age.   
 
 
Notified 
tuberculosis 
cases 
Estimated  
treatment failures or deaths Estimated 
number saved 
from treatment 
failure or death 
Country 
Current 
Dosing 
Proposed 
Dosing 
Angola* 102 7 5 2 
Bangladesh 957 51 27 24 
Brazil 888 54 48 6 
China 261 9 8 1 
DRC 5607 398 283 114 
Ethiopia 3452 244 161 83 
India 26,063 1442 799 643 
Indonesia 22,203 970 676 294 
Kenya 3903 253 195 57 
Mozambique 3841 257 186 71 
Myanmar 13,176 880 626 254 
Nigeria 2517 184 116 68 
Pakistan 16,880 846 558 288 
Philippines 16,573 836 529 307 
Russia 1025 62 56 6 
South Africa 9254 563 456 107 
Tanzania 4899 327 252 75 
Thailand 318 14 10 3 
Vietnam 589 22 18 5 
Zambia 794 55 39 15 
Total 133,302 7470 5047 2423 
 
Predictions were calculated using median probability of unfavorable outcome (Punf) and number 
of under-five notified tuberculosis cases (WHO), disaggregated by age. *=2016 notification data. 
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Figures 
 
 
Figure 1. Childhood tuberculosis dosing schematic.  
For the proposed guidelines, dosing is stratified by nutritional status (WAZ > 0, use weight-
based dosing; WAZ < 0, use age or expected weight dosing). Alternatively, a simplified dosing 
chart can be used to determine dose. WAZ = weight-for-age z-score. PGx = pharmacogenomics. 
FDC = fixed dose combination. 
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Figure 2. Underdosing prevalence with current WHO treatment guidelines.  
Bar segments represent the contribution of each age group to the overall underdosing prevalence 
in all (a) or underweight (b) children. DRC = Democratic Republic of the Congo. 
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Figure 3. Impact of malnutrition on rifampicin exposure target outcomes.  
Target outcomes are shown with respect to different measures of nutritional status (a) and 
severity of malnourishment, determined by weight-for-age z-score (b). 
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Figure 4. Rifampicin target exposure outcomes in high-burden tuberculosis countries. 
The proportion of children reaching the rifampicin exposure target across weight-for-age z-score 
(WAZ) is shown for each dosing scheme. Histogram shows the population distribution. DRC = 
Democratic Republic of the Congo. 
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